Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2
-
Daiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with
-
Daiichi Sankyo2019-12-12 16:00:02Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with
-
Daiichi Sankyo2019-08-22 10:15:01Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to
-
Daiichi Sankyo2019-08-07 13:30:01Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the
-
Daiichi Sankyo2019-08-07 13:30:01Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small
-
Daiichi Sankyo2019-08-07 13:30:01Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients
-
Daiichi Sankyo2019-10-15 11:27:12Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-]